<var id="ndj7z"><video id="ndj7z"><thead id="ndj7z"></thead></video></var>
<menuitem id="ndj7z"><strike id="ndj7z"><thead id="ndj7z"></thead></strike></menuitem>
<var id="ndj7z"></var>
<var id="ndj7z"><video id="ndj7z"></video></var>
<cite id="ndj7z"></cite>
<var id="ndj7z"></var>
<var id="ndj7z"></var>
<cite id="ndj7z"><strike id="ndj7z"><menuitem id="ndj7z"></menuitem></strike></cite> <cite id="ndj7z"><video id="ndj7z"></video></cite>
<cite id="ndj7z"><video id="ndj7z"><menuitem id="ndj7z"></menuitem></video></cite>
<var id="ndj7z"><strike id="ndj7z"></strike></var><var id="ndj7z"></var>
您好,歡迎訪問中山大學腫瘤防治中心官方網站!
內部網 職工郵箱 圖書館 OA系統 醫生門戶 English
院士風采 首席專家 臨床專家 科研學者 客座教授 人才名錄 護理專家
首頁
  • 謝小明

    職務:乳腺科主任
    職稱:教授、主任醫師、博士生導師
    專長:從事腫瘤和乳腺癌醫療、教學和科研工作二十多年,在乳腺疾病的診斷和治療方面擁有豐富的經驗。在腫瘤分子生物學和靶向治療分子機制方面研究成績突出。
        中山大學腫瘤防治中心乳腺科主任,中山大學“百人計劃”引進人才,教授、博士研究生導師,華南腫瘤學國家重點實驗室研究員,腫瘤生物技術研究室主任。美國M. D. Anderson癌癥中心訪問教授。2008年7月回國,與楊名添教授一起建立腫瘤防治中心乳腺科并擔任主任。2009年9月建立華南腫瘤學國家重點實驗室腫瘤生物技術研究室并擔任主任,2009年與法國讓佩林癌癥中心建立中法癌癥遺傳學聯合實驗室并擔任主任。目前是美國癌癥研究協會(AACR)、美國臨床癌癥研究協會(ASCO)和美國基因治療協會(ASGT)等會員,是《Chinese Journal of Cancer》編輯部責任編委、美國《Journal of Cancer》和《中華乳腺病雜志》責任編委,《Cancer Research》、《Human Gene Therapy》和《Annals of Surgical Oncology》等多家雜志的審稿人。是國家自然科學基金委一審、二審專家和廣東省自然科學基金委評審專家,廣東省醫學鑒定專家,廣州市醫療事故技術鑒定專家。

    醫療專長:
      從事腫瘤和乳腺癌醫療、教學和科研工作二十多年,在乳腺疾病的診斷、手術和綜合治療方面擁有豐富的經驗。在腫瘤分子生物學和靶向治療分子機制方面研究成績突出。

    門診時間:
    每周一、三上午。
      中山大學腫瘤防治中心乳腺科主任,教授、主任醫師、研究員、臨床醫學科學家、中山大學“百人計劃”引進人才、博士研究生導師、華南腫瘤學國家重點實驗室PI、腫瘤生物技術研究室主任,美國M. D. Anderson癌癥中心訪問教授。2008年7月回國,與楊名添教授一起建立腫瘤防治中心乳腺科并擔任主任。2009年9月建立華南腫瘤學國家重點實驗室腫瘤生物技術研究室并擔任主任,2009年與法國讓佩林癌癥中心建立中法癌癥遺傳學聯合實驗室并擔任主任。目前是美國癌癥研究協會(AACR)、美國臨床癌癥研究協會(ASCO)和美國基因治療協會(ASGT)等會員,中國研究型醫院學會乳腺專業委員會常委、中國抗癌協會腫瘤代謝委員會委員、中國健康促進會乳腺癌防治專家、衛生部醫療服務標準專業委員會專家。是《Global Journal of Epidemiology and Public Health》共同主編、 《Chinese Journal of Cancer》責任編委、美國《Journal of Tumor》副主編、《Journal of Cancer》和《中華乳腺病雜志》編委,《Cancer Research》、《Human Gene Therapy》和《Annals of Surgical Oncology》等多家雜志的審稿人。共發表論著170余篇,其中SCI論著150余篇,已獲得或申請中國美國發明專利11項,研制臨床前期產品10項,主持國家自然基金重點項目等30余項基金。是國家自然科學基金委一審和二審評審專家、教育部學位評審專家、中國博士后基金評審專家,廣東省自然科學基金委評審專家,廣東省醫學鑒定專家,廣州市醫療事故技術鑒定專家,廣東省保健協會首席專家,獲嶺南名醫和羊城好醫生稱號。  

    醫療專長:
      從事腫瘤和乳腺癌醫療、教學和科研工作二十多年,在乳腺疾病的診斷、手術治療、乳房重建和綜合治療方面擁有豐富的經驗,在腫瘤分子生物學和靶向治療分子機制研究方面成績突出。

    個人簡介:
      在中南大學湘雅醫學院于1986年獲醫學學士學位,1994年獲博士學位。1995-1997年在西班牙做博士后,1997-1999年在美國佛羅里達大學做博士后,1999-2003年在美國貝勒醫學院任副研究員。2003-2008年在美國德州大學M. D. Anderson癌癥中心任研究員,曾任分子和細胞腫瘤系轉化研究課題組負責人,2010.9-2010.10在法國讓佩林癌癥中心合作研究。長期致力于癌癥的基因調控,活體成像轉基因動物模型和癌癥的靶向基因治療等方面研究,發展了多套新穎的對乳腺癌、胰腺癌、前列腺癌、卵巢癌、肝癌等多種癌癥的靶向治療策略和臨床前期產品,與中國、美國、英國、日本、韓國及臺灣地區的多家研究機構開展了廣泛的交流和合作。 
      共發表論著170余篇,其中SCI論著150余篇(包括Cancer Cell, Nature Cell Biology,Science Signaling, Caner Research,Oncogene, Human Gene Therapy,Mol Cancer Therapeutics, Cancer Gene Therapy,Molecular Endocrinology,Digestive Diseases and Science等)。中英文專業書籍5本中各一章。其中以通訊作者/第一作者發表SCI論文90余篇,總影響因子380余分,1篇大于20(Cancer Cell,2007),以第一作者和共同作者發表論文總影響因子累計超600余分,他引共3800余次,其中第一作者論文單篇他引最高170余次,共同作者單篇他引最高500余次,H-Index 37。其中納米顆粒介導的VISA系統靶向治療胰腺癌的主要研究成果,發表在2007年7月份的Cancer Cell(IF值24.9)上。美國Science News上評論:“這種治療癌癥的方法是獨一無二的,對癌癥既有非常強的療效又非常特異”。美國ABC電視臺認為“這是癌癥治療的一個重大突破”。在論文發表后短期內,來自美國<<世界日報>>,以及中國、英國、俄國、德國、法國、西班牙、葡萄牙、意大利、荷蘭、希臘、阿拉伯、韓國、日本等世界各地的多家科學雜志和新聞媒體對該成就進行了200多次報道和高度的評價。已獲得中國美國發明專利11項,研制臨床前期產品10項,其中1項已部分轉讓給美國Pfizer(輝瑞)制藥公司,其中1項已經FDA批準,獲許進入I期臨床驗證,已部分轉讓給臺灣東洋制藥公司。先后承擔美國NIH、NCI重大課題5項?;貒?,實施臨床研究多項,主持中山大學II類引進人才基金、廣州市科技計劃、廣東省自然基金、廣東省科技計劃、教育部博士點基金和國家自然基金面上和重點項目等30余項,經費3000余萬元。

    研究方向:
    1.乳腺腫瘤的診斷及治療,乳腺癌干細胞及納米靶向治療,乳腺腫瘤分子遺傳學
    2.腫瘤學和分子醫學(腫瘤的發生發展機制,腫瘤早期診斷與生物治療等)
    3.細胞生物學
    4.影像醫學與生物醫學工程
    5.新型實驗動物模型

    發明專利:
    1.謝小明等。One type of the innovative syringe.中國專利號(1994): ZL 93233668.X.
    2.謝小明等。CANCER SPECIFIC PROMOTERS (Including breast cancer and ovarian cancer). USPT Patent. 癌癥靶向基因治療乳腺癌和卵巢癌. 美國專利申請號(11.2007):119430572  (AO-UTSC:995US)
    3.謝小明等。CANCER SPECIFIC PROMOTERS (Including breast cancer, pancreatic cancer, prostate cancer). USPT Patent. 癌癥靶向基因治療乳腺癌, 胰腺癌和卵巢癌. 美國專利號(2010):US7723104B2
    4.謝小明等。EZC-prostate (a transgenic mouse model)(Disclosure). License to Pfizer (美國) 2005
    5.謝小明等。一種可高效高特異滅殺乳腺癌細胞的藥物。中國專利號:201110371596.2。License to Guangzhou Pharmaceutical。
    6.謝小明等。一種可高效在體內外轉染基因的新型脂質體及其制備方法。中國專利申請號:201110300920.1
    7.謝小明等。一種在腫瘤細胞中高效高特異表達靶基因的載體T-VISA。中國專利申請號:201110300441.X
    8.謝小明等。一種可高效高特異滅殺乳腺癌細胞的藥物T-VISA-PEA15。中國專利號:201210063812.1
    9.謝小明等。一種可高效高特異滅殺P53基因突變型乳腺癌細胞的T-VISA-miR34脂質體。中國專利申請號:201210064390.X.
    10.謝小明等??煞€定傳代并保持原特性的乳腺癌干細胞系及其分離方法和應用。中國專利申請號:201510330647.5
    11.謝小明等。一種RNAcircEPSTII 及其在三陰乳腺癌上的應用。中國專利號:201710721878.8.

    主持研究基金:
    1.國家自然基金重點項目(31030061)。EZC-乳腺癌干細胞轉基因小鼠模型的建立及應用。200萬.2011-2014.
    2.國家自然基金面上項目(81872152)。POMC調控乳腺癌腦轉移的作用及其機制研究。57萬,2019-2022.
    3.國家自然基金面上項目(81672598)。LGR5調控乳腺癌干細胞的休眠作用與機制研究。57萬,2017-2020.
    4.國家自然基金面上項目(81472575)。利用基因剔除小鼠研究miR-34a抑制乳腺癌的分子機制。75萬.2015-2018.
    5.國家自然基金面上項目(81272514)。VISA-miR-34a高效納米系統靶向殺滅乳腺癌干細胞的作用及機制研究。65萬.2013-2016.
    6.廣東省科技(2015B090901050)。 一種可高效高特異殺滅乳腺癌的T-VISA-BikDD脂質體候選藥物的研究。產學研合作項目省協同創新與平臺環境建設專項基金。100萬元。2015-17
    7.廣東省科技(2015B020211002)。 一種高效抗乳腺癌T-VISA-PEA15脂質體候選藥物的研究。社會發展領域 省協同創新與平臺環境建設專項基金。100萬元。2015-17
    8.廣州市民生科技項目。乳腺癌干細胞調控研究。廣州市科技。100萬,2016-2018.
    9.中山大學腫瘤防治中心“臨床科學家”基金。中山大學腫瘤防治中, 150萬元。2015-17
    10.中山大學腫瘤防治中心“臨床研究”基金(308計劃)。中山大學腫瘤防治中(2014-FXY-093), 80萬元。2015-17
    11.教育部高等學校博士學科點專項科研基金.乳腺癌干細胞的生物學特征及靶向治療研究(20090171110078)。6萬元(2009).
    12. 教育部回國人員啟動基金. 乳腺癌靶向治療。4萬元 (2009).
    13.廣東省科技基金(2013B060300009)。miR-34a抑制乳腺癌的作用及機制研究。10萬元. 2014-2015.
    14.廣東省自然基金(9151008901000124)。應用“VISA”系統高效靶向殺滅乳腺癌干細胞的研究。5萬元. 2009-2011.
    15.廣州市科技計劃(2014J4100169). VISA-miR-26a高效納米顆粒抑制乳腺癌生長的機制研究。6萬元。2013.7-2015.6
    16.廣州市科技計劃. CD44-VISA-miR-200c高效納米系統靶向殺滅乳腺癌干細胞的研究. 6萬元。2010-7-2012.6
    17.中山大學“985” 計劃(2008089)。乳腺癌納米靶向治療機制。40萬元, 2008-2010
    18.中山大學. 2014年度“中山大學科研助手計劃”.5萬元
    19.中心國際合作項目(美國M.D.Anderson癌癥中心)。 Development of biomarkers to predict cetuximab resistance. 30萬。2014-2016
    20.華南腫瘤學重點實驗室。含有1,8-萘酰亞胺單體的聚乙烯亞胺類非病毒基因載體的研究. 5萬元. 2009-2010
    21.華南腫瘤學重點實驗室。前列腺癌細胞系腫瘤干細胞的分離、鑒定及其生物學特性和相關機制研究. 5萬元. 2010-2011
    22.華南腫瘤學重點實驗室. 乳腺癌靶向治療的研究. 15萬元. 2010-2011
    23.華南腫瘤學重點實驗室. 乳腺癌靶向治療的研究. 8萬元. 2011-2012
    24.華南腫瘤學重點實驗室 乳腺癌靶向治療的研究. 8萬元. 2012-2013
    25.華南腫瘤學重點實驗室。 乳腺癌靶向治療的研究. 15萬元. 2013-2014
    26.華南腫瘤學重點實驗室 。乳腺癌靶向治療的研究. 14.8萬元. 2014-2015
    27.華南腫瘤學重點實驗室。乳腺癌靶向治療的研究15萬元,2015-2016
    28.乳腺癌靶向治療的研究。華南腫瘤學重點實驗室。 15萬元,2016-2017
    29.華南腫瘤學重點實驗室。乳腺癌靶向治療的研究7萬元,2017-2018
    30.ZY001的化學合成及免疫原性評價。白云山中一藥業有限公司合作基金, 15萬元。2015-17
    31.中國癌癥基金會.中國乳腺癌臨床流行病學多中心研究. 5.5萬元. 2009.9-2010.12
    32.Roche公司。血清her-2/neu 水平在乳腺癌中的價值研究. 5萬元. 2010.9-2011.8
    33.Co-Investigator, E1A Gene Therapy in Breast Cancer, RO1 CA058880, National Cancer Institute, NIH $261,000 ADC, 08/01/1997-01/31/2005.
    34.Co-Investigator, “Targeting Breast Cancer-Specific Gene Therapy’ in NIH SPORE grant in Breast Cancer (5P50CA116199-03), 2005-2010.
    35.Co-Investigator, “Development of Novel Gene Therapy for Pancreatic Cancer” in NIH SPORE grant in Pancreatic Cancer (P20 CA101936), P20 CA101936-01, NCI,NIH. $225,000 (ADC). 07/01/2003-06/30/2008.
    36. Co-Investigator. “Development of E1A Gene Therapy in Ovarian Cancer” in NIH SPORE grant in Ovarian Cancer (5P50CA083639-08), 2005-2010. 
    37.Co-PI。 Ideal Development Award ($560,000), DOD (Department of Defense).USA. 2007. 
    38.Co-Investigator, Topfer Funds.2005-2010.
    39.. Co-Investigator, M. D. Anderson Cancer Center Support Grant CA16672, 2005.
    40.. Co-Investigator, NIH Grant R01-CA87569, Baylor College of Medicine, 2001-2006.

    臨床試驗:
    2003-Present  乳腺癌臨床試驗
      1. E1A gene therapy for breast cancer; E1A 基因治療乳腺癌
      2. BikDD gene therapy for breast cancer. BikDD基因治療乳腺癌 (prepared, under process of FDA)
      3. E10A (Adenovirus expressing human endostatin) for recurrent breast cancer therapy (approved by SFDA).. 
      4. 喜滴克治療乳腺癌的IV期臨床試驗, 2011-2012
    2005-present  胰腺癌臨床試驗
      1. BikDD gene therapy for pancreatic cancer. BikDD基因治療胰腺癌 (prepared, under process of FDA)
    2005-present  卵巢癌臨床試
      1. E1A gene therapy and SAHA for ovarian cancer. E1A 基因治療和SAHA治療卵巢癌
      2. BikDD gene therapy for ovarian cancer. BikDD基因治療卵巢癌 (prepared, under process of FDA)
    308計劃:三陰乳腺癌保乳和改良根治隨機對照研究。2015.8
    5010計劃:ER(-α)/PR陰性/ER-β陽性乳腺癌術后輔助他莫昔芬內分泌治療有效性和安全性的隨機對照臨床試驗。2015.-2024

    代表性論文
    (第一和/或通訊作者(?),92篇,影響因子385):
    1.Tang H, Chen B, Liu P, Xie X, He R, Zhang L, Huang X, Xiao X, Xie X(?).SOX8 acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. Carcinogenesis. 2019 Feb 27. pii: bgz034. doi: 10.1093/carcin/bgz034. [Epub ahead of print] (IF:5.072)
    2.Zou Y, Zheng S, Xiao W, Xie X, Yang A, Gao G, Xiong Z, Xue Z, Tang H, Xie X(?).circRAD18 sponges miR-208a/3164 to promote triple-negative breast cancer progression through regulating IGF1 and FGF2 expression.Carcinogenesis. 2019 Apr 17. pii: bgz071. doi: 10.1093/carcin/bgz071. [Epub ahead of print] (IF:5.072)
    3.Tang H, Huang X, Wang J, Yang L, Kong Y, Gao G, Zhang L, Chen ZS, Xie X(?).circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. Mol Cancer. 2019 Feb 11;18(1):23. doi: 10.1186/s12943-019-0946-x. (IF:7.776)
    4.Xie X, Wang J, Shi D, Zou Y, Xiong Z, Li X, Zhou J, Tang H, Xie X(?).Identification of a 4-mRNA metastasis-related prognostic signature for patients with breast cancer. J Cell Mol Med. 2019 Feb;23(2):1439-1447. doi: 10.1111/jcmm.14049. Epub 2018 Nov 28 ( IF:4.302)
    5.Chen B, Wei W, Huang X, Xie X, Kong Y, Dai D, Yang L, Wang J, Tang H(?), Xie X(?). circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression.Theranostics. 2018 Jul 1;8(14):4003-4015. doi: 10.7150/thno.24106. eCollection 2018. (IF:8.537)
    6.Chen B, Tang H, Chen X, Zhang G, Wang Y, Xie X, Liao N. Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer. Cancer Manag Res. 2018 Dec 21;11:179-190. doi: 10.2147/CMAR.S187151. 
    7.Xie X, Tan W, Chen B, Huang X, Peng C, Yan S, Yang L, Song C, Wang J, Zheng W, Tang H(?), Xie X(?).Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical-related features for axillary lymph node metastasis in early-stage invasive breast cancer. Int J Cancer. 2018 May 1;142(9):1901-1910. doi: 10.1002/ijc.31208. Epub 2018 Jan 12(IF:7.36)
    8.Huang X, Xie X, Liu P, Yang L, Chen B, Song C, Tang H(?), Xie X(?).Adam12 and lnc015192 act as ceRNAs in breast cancer by regulating miR-34a. Oncogene. 2018 Jul 24. doi: 10.1038/s41388-018-0410-1. [Epub ahead of print] (IF:6.854)
    9.Luo L, Tang H, Ling L, Li N, Jia X, Zhang Z, Wang X, Shi L, Yin J1, Qiu N, Liu H, Song Y, Luo K, Li H, He Z, Zheng G(?), Xie X(?). LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer. Oncogene. 2018 Jul 12. doi: 10.1038/s41388-018-0396-8. [Epub ahead of print] (IF:6.854)
    10.Wu J, Shuang Z, Zhao J, Tang H, Liu P, Zhang L, Xie X(?), Xiao X(?). Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer. Biomed Pharmacother. 2018 Jan;97:1275-1281. doi: 10.1016/j.biopha.2017.11.055. Epub 2017 Dec 14 (IF:3.457)
    11.Kong Y, Lyu N, Wu J, Tang H, Xie X, Yang L, Li X, Wei W, Xie X(?). Breast cancer stem cell markers CD44 and ALDH1A1 in serum: distribution and prognostic value in patients with primary breast cancer. Journal of Cancer 2018, Vol. 9 018; 9(20): 3728-3735. doi: 10.7150/jca.28032 (IF:3.249)
    12.Li X, Dai D, Chen B, Tang H, Xie X(?), Wei W(?). The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis. J Cancer. 2018 Feb 12;9(5):861-871. doi: 10.7150/jca.23367. eCollection 2018. (IF:3.249)
    13.Xiao W, Zheng S, Liu P, Zou Y, Xie X, Yu P, Tang H(?), Xie X(?). Risk factors and survival outcomes in patients with breast cancer and lung metastasis: a population-based study. Cancer Med. 2018 Mar;7(3):922-930. doi: 10.1002/cam4.1370. Epub 2018 Feb 23. (IF:3.202)
    14.Xiao W, Zheng S, Yang A, Zhang X, Liu P, Xie X, Tang H, Xie X(?). Incidence and Survival Outcomes of Breast Cancer with Synchronous Hepatic Metastases: A Population-Based Study. J Cancer. 2018 Oct 21;9(23):4306-4313. doi: 10.7150/jca.29190. eCollection 2018. (IF:3.249)
    15.Xiao W, Zheng S, Yang A, Zhang X, Zou Y, Tang H, Xie X(?). Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study. Cancer Manag Res. 2018 Nov 5;10:5329-5338. doi: 10.2147/CMAR.S176763. eCollection 2018 (IF:3.702)
    16.Li X, Dai D, Chen B, Tang H, Xie X(?), Wei W(?). Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients. Dis Markers. 2018 May 2;2018:9863092. doi: 10.1155/2018/9863092. eCollection 2018. Review.
    (IF:2.949)
    17.Xie X, Wang J, Shi D, Zou Y, Xiong Z, Li X, Zhou J, Tang H, Xie X. Identification of a 4-mRNA metastasis-related prognostic signature for patients with breast cancer. J Cell Mol Med. 2018 Nov 28. doi: 10.1111/jcmm.14049. [Epub ahead of print] (IF:4.302)
    18.Li X, Dai D, Chen B, Tang H, Xie X(?), Wei W(?)..Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials. PLoS One. 2018 Feb 6;13(2):e0192464. doi: 10.1371/journal.pone.0192464. eCollection 2018. (IF:2.766)
    19.Xie X, Huang X, Tang H, Ye F, Yang L, Guo X, Tian Z, Xie X, Peng C(?), Xie X(?). Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling.Curr Cancer Drug Targets. 2018;18(6):592-599. doi: 10.2174/1568009617666171024165657. (IF:2.626)
    20.Tang H, Peng F, Huang X, Xie X, Chen B, Shen J, Gao F, You J, Xie X(?), Chen J(?). Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-β- catenin Signaling in Breast Cancer. Curr Cancer Drug Targets. 2018;18(4):390-399. doi: 10.2174/1568009617666170914155355. (IF:2.626)
    21.Wu J, Liu P, Tang H, Shuang Z, Qiu Q, Zhang L, Song C, Liu L, Xie X(?), Xiao X(?). FOXP2 Promotes Tumor Proliferation and Metastasis by Targeting GRP78 in Triple-negative Breast Cancer. Curr Cancer Drug Targets. 2018;18(4):382-389. (IF:2.626)
    22.Li X, Dai D, Chen B, Tang H, Xie X(?), Wei W(?). Determination of the prognostic value of preoperative CA15-3 and CEA in predicting the prognosis of young patients with breast. Cancer. Oncol Lett. 2018 Oct;16(4):4679-4688. doi: 10.3892/ol.2018.9160. Epub 2018 Jul 17 . (IF:1.664)
    23.Xiao W, Zou Y, Zheng S, Hu X, Liu P, Xie X, Yu P, Tang H, Xie X(?). Primary tumor resection in stage IV breast cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2018 Oct;44(10):1504-1512. doi: 10.1016/j.ejso.2018.08.002. Epub 2018 Aug . (IF:3.688)
    24.Lin X, Chen W, Wei F, Zhou BP, Hung MC, Xie X(?).Nanoparticle Delivery of miR-34a Eradicates Long-term-cultured Breast Cancer Stem Cells via Targeting C22ORF28 Directly. Theranostics. 2017 Oct 17;7(19):4805-4824. doi: 10.7150/thno.20771. eCollection 2017.(IF 8.712)
    25.Lin X, Chen W, Wei F, Zhou BP, Hung MC, Xie X(?). POMC maintains tumor-initiating properties of tumor tissue-derived long-term-cultured breast cancer stem cells. Int J Cancer. 2017 Jun 1;140(11):2517-2525. doi: 10.1002/ijc.30658. Epub 2017 Mar 16. (IF 6.513)
    26.Wang J, Song C, Tang H, Zhang C, Tang J, Li X, Chen B, Xie X(?). miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. Breast Cancer Res. 2017 Jun 19;19(1):72. doi: 10.1186/s13058-017-0865-y. (IF 6.354)
    27.Huang X, Xie X, Wang H, Xiao X, Yang L, Tian Z, Guo X, Zhang L, Tang H, Xie X(?).PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a.J Exp Clin Cancer Res. 2017 Sep 15;36(1):129. doi: 10.1186/s13046-017-0593-2. (IF 5.189)
    28.Chen B, Wang J, Dai D, Zhou Q, Guo X, Tian Z, Huang X, Yang L, Tang H, Xie X(?).AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.J Exp Clin Cancer Res. 2017 May 12;36(1):65. doi: 10.1186/s13046-017-0522-4. (IF 5.189)
    29.Wang N, Wang Q, Tang H, Zhang F, Zheng Y, Wang S, Zhang J, Wang Z(?), Xie X(?).Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells.J Exp Clin Cancer Res. 2017 Dec 2;36(1):172. doi: 10.1186/s13046-017-0635-9. (IF 5.189)
    30.He X, Ye F, Zhao B, Tang H, Wang J, Xiao X, Xie X(?).Risk factors for delay of adjuvant chemotherapy in non-metastatic breast cancer patients: A systematic review and meta-analysis involving 186982 patients. PLoS One. 2017 Mar 16;12(3):e0173862. doi: 10.1371/journal.pone.0173862. (IF 3.362)
    31.He X, Ye F, Li M, Yu P, Xiao X, Tang H, Xie X(?).Application of a novel prognostic invasive lesion index in ductal carcinoma in situ with minimal invasion of the breast.Cancer Med. 2017 Nov;6(11):2489-2496. doi: 10.1002. (IF 2.916)
    32.He XF, Ye F, Wen JH, Li SJ, Huang XJ, Xiao XS, Xie XM.High Residual Tumor Rate for Early Breast Cancer Patients Receiving Vacuum-assisted Breast Biopsy.J Cancer. 2017 Feb 11;8(3):490-496. doi: 10.7150/jca.17305. eCollection 2017. (IF 2.916)
    33.Wen J, Yang Y, Liu P, Ye F, Tang H, Huang X, Zhong S, Xie X(?).Development and validation of a nomogram for predicting survival on the base of modified lymph node ratio in breast cancer patients. Breast. 2017 Jun;33:14-22. doi: 10.1016. (IF 2.801)
    34.Li X, Tang H, Wang J, Xie X, Liu P, Kong Y, Ye F, Shuang Z, Xie Z, Xie X(?). The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer. Breast. Breast. 2017 Apr;32:1-6. doi: 10.1016. (IF 2.801)
    35.Lin X, Li J, Ying M, Wei F, Xie X(?). Diabetes Increases Morbidities of Colonic Diverticular Disease and Colonic Diverticular Hemorrhage: A Systematic Review and Meta-Analysis. Am J Ther. 2017 Mar/Apr;24(2):e213-e221. doi: 10.1097. (IF 1.588)
    36.Liu P, Ye F, Xie X, Li X, Tang H, Li S, Huang X, Song C, Wei W (?),Xie X(?). mir-101-3p is a key regulator of tumor metabolism in triple negative breast cancer targeting AMPK. Oncotarget. 2016 Apr 28. 7(23): 35188-98.(IF 5.168)
    37.Wen J, Ye F, He X, Li S, Huang X, Xiao X, Xie X(?). Development and validation of a prognostic nomogram based on the log odds of positive lymph nodes (LODDS) for breast cancer. Oncotarget. 2016 Apr 12;7(15):21046-53. (IF 5.168)
    38.Tan W, Xie X, Li L, Tang H, Ye X, Chen L, Tang W, Gao J, Pan L, Zhang X, Ye F, Li X, Yang L, Xie X(?), Zheng W(?). Diagnostic and prognostic value of serum MACC1 in breast cancer patients. Oncotarget. 2016 Oct 25. doi: 10.18632. (IF 5.168)
    39.Xiao X, Huang X, Ye F, Chen B, Song C, Wen J, Zhang Z, Zheng G, Tang H (?),Xie X(?). The miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer Sci Rep. 2016 Feb 23;6:21735. (IF 4.259)
    40.Song C, Zhang L, Wang J, Huang Z, Li X, Wu M, Li S, Tang H (?),  Xie X(?). High expression of microRNA-183/182/96 cluster as a prognostic biomarker for breast cancer.Sci Rep. 2016 Apr 13;6:24502. (IF 4.259)
    41.Chen B , Dai D, Tang H, Chen X, Ai X, Huang X, Wei W (?),Xie X(?). Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer.  J. Cancer  2016; 7(15): 2309-2316. (IF 2.916)
    42.Dai D, Chen B, Wang B, Tang H, Li X, Zhao Z, Li X, Xie X(?), Wei W. Pretreatment TG/HDL-C Ratio Is Superior to Triacylglycerol Level as an Independent Prognostic Factor for the Survival of Triple Negative Breast Cancer Patients. J Cancer. 2016 Aug 7;7(12):1747-1754. (IF 2.916)
    43.Chen B, Dai D, Tang H, Ai X, Chen X, Zhang X, Li Z, Xie X(?). Pretreatment Hematocrit Is Superior to Hemoglobin as a Prognostic Factor for Triple Negative Breast Cancer. PLoS One. 2016 Nov 16;11(11):e0165133. (IF 2.806)
    44.Dai D, Chen B , Tang H, Wang B, Zhao Z, Xie X(?), Wei W (?).Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients.PLoS One. 2016 Aug 25;11(8):e0161902. (IF 2.806)
    45.Huang X, Li X, Xie X, Ye F, Chen B, Song C, Tang H (?),  Xie X(?). High expressions of LDHA and AMPK as prognostic biomarkers for breast cancer. Breast. 2016 Sep 3;30:39-46. (IF 2.801)
    46.Xie X, Tang H, Liu P, Kong Y, Wu M, Xiao X, Yang L, Gao J, Wei W, Lee J, Bartholomeusz C, Ueno NT(?), Xie X(?).  Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Lett.  2015 Jan 28; 356(2 Pt B):374-81. (IF: 6.375)
    47.Chen B, Tang H, Liu X, Liu P, Yang L, Xie X, Ye F, Song C, Xie X(?), Wei W(?). miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer. Cancer Lett. 2015 Jan 28;356(2 Pt B):410-7. (IF: 6.375)
    48.Liu P, Tang H, Chen B, He Z, Deng M, Wu M, Liu X, Yang L, Ye F, Xie X(?). miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer. Cancer Lett. 2015 Feb 1;357(1):384-92. (IF: 6.375)
    49.Yang L, Tang H, Kong Y, Xie X, Chen J, Song C, Liu X, Ye F, Li N, Wang N,  Xie X(?). LGR5 Promotes Breast Cancer Progression and Maintains Stem-Like Cells Through Activation of Wnt/β-Catenin Signaling.Stem Cells. 2015 Oct;33(10):2913-24. (IF: 5.599)
    50.Song C, Liu L, Pei X, Liu X, Yang L, Ye F, Xie X, Chen J, Tang H (*), Xie X(?). miR-200c inhibits breast cancer proliferation by targeting KRAS. Oncotarget. 2015 Oct 27; 6(33):34968-78. (IF: 5.168)
    51.Liu X, Tang H, Chen J, Song C, Yang l, Wang N, XieX, Lin X,  Xie X(?). MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer. Oncotarget. 2015 Aug 21;6(24):20070-83. (IF: 5.168)
    52.Wang J, Zhang C, Chen K, Tang H, Tang J, Song C, Xie X(?). ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer. Breast Cancer Res Treat. 2015 Jul;152(2):255-69. (IF:3.626)
    53.Lin X, Chen W, Wei F, Ying M, Wei W, Xie X(?). Night-shift work increases morbidity of breast cancer and all-cause mortality: a meta-analysis of 16 prospective cohort studies. Sleep Med. 2015 Nov;16(11):1381-7. (IF:3.391)
    54.Wen J, Ye F, Li S, Huang X, Yang L, Xiao X, Xie X(?).The Practicability of a Novel Prognostic Index (PI) Model and Comparison with Nottingham Prognostic Index (NPI) in Stage I-III Breast Cancer Patients Undergoing Surgical Treatment.PLoS One. 2015 Nov 23;10(11):e0143537. (IF: 2.806)
    55.Wen J, Yang Y, Ye F, Huang X, Li S, Wang Q, Xie X(?). The preoperative plasma fibrinogen level is an independent prognostic factor for overall survival of breast cancer patients who underwent surgical treatment. Breast. 2015 Dec;24(6):745-50.  (IF: 2.801)
    56.Jiao S, Liu W, Wu M, Peng C, Tang H,  Xie X(?). Nrdp1 expression to predict clinical outcome and efficacy of adjuvant anthracyclines-based chemotherapy in breast cancer: \newline A retrospective study. Cancer Biomark. 2015 Jan 1;15(2):115-23. (IF:2.274)
    57.Lin X, Li J, Chen W, Wei F, Ying M, Wei W,  Xie X(?). Diabetes and risk of anastomotic leakage after gastrointestinal surgery. J Surg Res. 2015 Jun 15;196(2):294-301. (IF:2.187)
    58.Wen J, Ye F, Huang X, Li S, Yang L, Xiao X, Xie X(?). Prognostic Significance of Preoperative Circulating Monocyte Count in Patients With Breast Cancer: Based on a Large Cohort Study. Medicine (Baltimore). 2015 Dec;94(49):e2266. (IF: 1.803)
    59.Tang H, Liu P, Yang L, Xie X, Ye F, Wu M, Liu X, Chen B, Zhang L, Xie X(?).miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer. Mol Cancer Ther. 2014 Dec;13(12):3185-97. (IF: 6.107)
    60.Xie X(?), Kong Y, Tang H, Yang L, Hsu JL, Hung MC. Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells. Mol Cancer Ther. 2014 Jul;13(7):1813-25. (IF: 6.107)
    61.Ye F, Tang H, Liu Q, Xie X, Wu M, Liu X, Chen B, Xie X. (?) miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family. J Transl Med. 2014 Jan 21;12:17. doi: 10.1186/1479-5876-12-17.
    62.Tang H, Xie X , Guo J, Wei W, Wu M, Liu P, Kong Y, Yang L, Hung MC, Xie X(?). Efficient systemic DNA delivery to the tumor by self-assembled nanoparticle. J Nanopart Res. 2014.16.2213.
    63.Xiao X, Chen B, Liu X, Liu P, Zheng G, Ye F, Tang H,  Xie X(?). Diallyl disulfide suppresses SRC/Ras/ERK signaling-mediated proliferation and metastasis in human breast cancer by up-regulating miR-34a. PLoS One. 2014 Nov 14;9(11):e112720. (IF: 3.234)
    64.Jiao S, Wu M, Ye F, Tang H, Xie X, Xie X(?). BikDDA, a Mutant of Bik with Longer Half-Life Expression Protein, Can Be a Novel Therapeutic Gene for Triple-Negative Breast Cancer. PLoS One. 2014 Mar 17;9(3):e92172. 
    65.Lin X, Wu M, Liu P, Wei F, Li L, Tang H, Xie X, Liu X, Yang L, Xie X(?). Up-regulation and worse prognostic marker of cytoplasmic TARBP2 expression in obstinate breast cancer. Med Oncol. 2014 Apr;31(4):868. doi: 10.1007/s12032-014-0868-9. Epub 2014 Feb 22.
    66.Wang J, Zhang X, He J, Yang M, Tang J, Li X, Tang H, Xie X(?). Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast. Med Oncol. 2014 Sep;31(9):172. doi: 10.1007/s12032-014-0172-8. (IF: 2.058)
    67.Wang K, Ren Y, Huang R, He J, Feng W, Kong Y, Xu F, Zhao L, Song Q, Li J, Zhang B, Fan J, Xie X(?), Zheng S, Qiao YL. Application of intraoperative frozen section examination in the management of female breast cancer in China: a nationwide, multicenter 10-year epidemiological study. World J Surg Oncol. 2014 Jul 18;12:225. doi: 10.1186/1477-7819-12-225.
    68.Yang L, Li N, Wang S, Kong Y, Tang H, Xie X, Xie X(?). Lack of Association Between the Matrix Metalloproteinase-2 -1306C>T Polymorphism and Breast Cancer Susceptibility: a Meta-analysis.Asian. Pac J Cancer Prev. 2014;15(12):4823-7.
    69.Tang H, Deng M, Tang Y, Xie X, Guo J, Kong Y, Ye F, Su Q and  Xie X(?).miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression. Clinical Cancer Research 2013 Oct 15;19(20):5602-12. (IF: 7.837)
    70.Tang H, Kong Y, Guo J, Tang Y, Xie X, Yang L, Su Q, Xie X(?). Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22. Cancer Lett. Cancer Lett. 2013 Oct 28;340(1):72-81 (IF:4.258)
    71.Li L, Yuan L, Luo J, Gao J, Guo J, Xie X(?). MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med. 2013 May;13(2):109-17.(IF:2.397)
    72.Kong Y, Wang J, Liu W, Chen Q, Yang J, Wei W, Wu M, Yang L, Xie X, Lv N, Guo J, Li L, Gao J, Xie X(?), Dai S(?). Cytokeratin19-2g2, a novel fragment of cytokeratin19 in serum, indicating a more invasive behavior and worse prognosis in breast cancer patients. PLoS One. 2013;8(2):e57092. (IF:3.73)
    73.Kong Y, Yang L, Tang H, Lv N, Xie X, Li J, Guo J, Li L, Wu M, Gao J, Yang H, Tang Z, He J, Zhang B, Li H, Qiao Y, Xie X?).A nation-wide multicenter retrospective study of the epidemiological, pathological and clinical characteristics of breast cancer in situ in chinese women in 1999 - 2008. PLoS One. 2013;8(2):e57092.. (IF:3.73)
    74.Gao J, Li L, Wu M, Liu M, Xie X, Guo J, Tang H, Xie X(?). MiR-26a Inhibits Proliferation and Migration of Breast Cancer through Repression of MCL-1. PLoS One. 2013 Jun 4;8(6):e65138. (IF:3.73)
    75.Guo J, Li W, Shi H, Xie X, Li L, Tang H, Wu M, Kong Y, Yang L, Gao J, Liu P, Wei W, Xie X(?). Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. Mol Cell Biochem. 2013 Oct;382(1-2):103-11. (IF:2.392)
    76.Wang J, Xie X(?), Wang X, Tang J, Pan Q, Zhang Y, Di M. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: A meta-analysis. Surg Oncol. 2013;222(4):247-55 (IF:2.136)
    77.Li X, Feng YF, Wei WD, Liu P, Xie ZM, Wang J, Xie X(?). Signet-ring cell carcinoma of the breast: a case report. World J. of Surgical oncology. 2013;11:183-186. (IF: 1.092)
    78.Wu MQ, Hu P, Gao J, Wei WD, Xiao XS, Tang HL, Li X, Ge QD, Jia WH, Liu RB, Xie X (?).Low expression of tyrosine-protein phosphatase nonreceptor type 12 is associated with lymph node metastasis and poor prognosis in operable triple-negative breast cancer. Asian Pac J Cancer Prev. 2013;14(1):287-92. (IF:1.271)
    79.Xiao X, Tang H, Xie X, Li L, Kong Y, Wu M, Yang L, Gao J, Wei W and Xie X(?).Metastatic axillary lymph node ratio(LNR) is prognostically superior to pN staging in patients with breast cancer -- results from a single institution study of 804 Chinese patients. Asian Pac J Cancer Prev. 2013;14(1):287-92. (IF:1.271)
    80.Li L, Xie X, Luo J, Wei W , Xi S, Guo J, Kong Y, Wu M, Gao J, Xie Z, Tang J, Wang X, Yang M, Hung MC, X Xie (?). Targeted Expression of miR-34a by T-VISA System Suppresses Tumor Cell Growth and Invasion in Breast Cancer. Mol Therapy; 2012; 20(12):2326-2334 (IF:6.873)
    81.Xie X, L Li, X Xiao, J Guo, Y Kong, M Wu, W Liu, G Gao, J L. Hsu, W Wei, M-C Hung (?) and X Xie(?). Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Mol Cancer Ther.2012 ;11(9);1915-1924. (IF:5.226)
    82.Wu M, Wei W, Xiao X, Guo J, Xie X, Li L, Kong Y, Lv N, Jia W, Zhang Y, Xie X(?). Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol. 2012 ; 3240-3249 (IF:2.14)
    83.Su Y, Tang LY, Chen LJ, He JR, Su FX, Lin Y, Chen WQ, Xie X(?), Ren ZF(?). Joint Effects of Febrile Acute Infection and an Interferon-γ Polymorphism on Breast Cancer Risk. PLoS One. 2012;7(5):e37275. (IF:4.092)
    84.Kong Y, Dai S, Xie X, Xiao X, Lv N, Guo J, Li L, Jia W, Zhang Y, Liu W, Wei W, Xie X(?). High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. J Cancer Res Clin Oncol. 2012; 2012;138(2):275-84. (IF:2.558)
    85.Lv N, Lin S, Xie Z, Tang J, Ge Q, Wu M, Xie X, Xie X(?), Wei W(?). Absence of evidence for epidermal growth factor receptor and human homolog of the Kirsten rat sarcoma-2 virus oncogene mutations in breast cancer. Cancer Epidemiol. 2012;36(4);341-346. (IF:2.010)
    86.Li L, Xie X, Luo J, Wei W , Xi S, Guo J, Kong Y, Wu M, Gao J, Xie Z, Tang J, Wang X, Yang M, Hung MC, Xie X, Guo J, Kong Y, Xie GX, Li L, Lv N, Xiao X, Tang J, Wang X, Liu P, Yang M, Xie Z, Wei W, Xie X(?).Targeted expression of E. coli purine nucleoside phosphorylase and Fludara for prostate cancer therapy. J Gene Med. 2011;13:680-691. (IF:3.079)
    87.A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Therapeutics. 2009; 8(8):2375-82. (IF: 5.225).
    88.Xie, X(?)., Xia, W., Li, Z., Kuo, H-P.,Liu, Y., Li, Z., Ding, Q., Zhang, S., Spohn, W., Yang, Y., Wei, Y., Lang, J-Y., Evans, D.B., Chiao, P.J., Abbruzzese J.L. and Hung, M-C. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell, 2007;12(July10):52-65. (IF: 26.925).
    89.Xie, X(?), Z Luo, KM Slawin, and DM Spencer. The EZC-Prostate Model: Non-invasive prostate imaging in living mice. Mol Endocrinol 2004;18(3):722-732. (IF:5.389).
    90.Xie X(?), X Zhou, Y Liu, K Slawin, and D Spencer. Adenovirus-mediated tissue-targeted expression of a caspase 9-based artificial death switch for the treatment of prostate cancer. Cancer Res 2001; 61: 6795-804. (IF: 8.234).
    91.Xie X(?), X Zhao, Y Liu, CYF Young, DJ Tindall, K Slawin, and D Spencer. Robust prostate-specific expression for targeted gene therapy based on human kallikrein 2 (hK2) promoter. Human Gene Therapy 2001;12(5): 549-61. (IF: 4.829).
    92.Xie X(?), CE Forsmark, and JY Lau. Effect of bile and pancreatic juice on adenovirus-mediated gene delivery: Implications on the feasibility of gene delivery through ERCP. Digestive Diseases and Sciences 2000; 45(2):230-36. (IF:1.583). 

    (共同作者63篇,影響因子350):
    93.He R, Liu P, Xie X, Zhou Y, Liao Q, Xiong W, Li X, Li G, Zeng Z, Tang H.circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a.J Exp Clin Cancer Res. 2017 Oct 16;36(1):145. doi: 10.1186/s13046-017-0614-1.
    94.Zhang W, Wang MY, Wei XL, Lin Y, Su FX, Xie XM, Tang LY, Ren ZF. Associations of Epstein-Barr Virus DNA in PBMCs and the Subtypes with Breast Cancer Risk.J Cancer. 2017 Aug 25;8(15):2944-2949. doi: 10.7150/jca.20330. eCollection 2017.
    95.Xie ZM, Sun J, Hu ZY, Wu YP, Liu P, Tang J, Xiao XS, Wei WD, Wang X, Xie XM, Yang MT.Survival outcomes of patients with lobular carcinoma in situ who underwent bilateral mastectomy or partial mastectomy.Eur J Cancer. 2017 Sep;82:6-15. doi: 10.1016/j.ejca.2017.05.030. Epub 2017 Jun 21.
    96.Zhu RM, Lin W, Zhang W, Ren JT, Su Y, He JR, Lin Y, Su FX, Xie XM, Tang LY, Ren ZF.Modification effects of genetic polymorphisms in FTO, IL-6, and HSPD1 on the associations of diabetes with breast cancer risk and survival.PLoS One. 2017 Jun 7;12(6):e0178850. doi: 10.1371/journal.pone.0178850. eCollection 2017.
    97.Liu Y, Zhang J, Huang R, Feng WL, Kong YN, Xu F, Zhao L, Song QK, Li J, Zhang BN, Fan JH, Qiao YL, Xie XM, Zheng S, He JJ, Wang K.Influence of occupation and education level on breast cancer stage at diagnosis, and treatment options in China: A nationwide, multicenter 10-year epidemiological study.Medicine (Baltimore). 2017 Apr;96(15):e6641. doi: 10.1097/MD.0000000000006641
    98.Zhang J, Li X, Huang R, Feng WL, Kong YN, Xu F, Zhao L, Song QK, Li J, Zhang BN, Fan JH, Qiao YL, Xie XM, Zheng S, He JJ, Wang K.A nomogram to predict the probability of axillary lymph node metastasis in female patients with breast cancer in China: A nationwide, multicenter, 10-year epidemiological study.Oncotarget. 2017 May 23;8(21):35311-35325. doi: 10.18632/oncotarget.13330.
    99.Li Q, Yang Z, Fan J, He J, Zhang B, Yang H, Xie X, Tang Z, Li H, Qiao Y, Zhang P.A nation-wide multicenter 10-year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients.Oncotarget. 2017 Mar 22;8(44):75864-75873. doi: 10.18632/oncotarget.16439. eCollection 2017 Sep 29.
    100.Gao F, Zhang J, Fu C, Xie X, Peng F, You J, Tang H, Wang Z, Li P, Chen J. iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability.Int J Nanomedicine. 2017 Jun 1;12:4147-4162. doi: 10.2147/IJN.S134148. eCollection 2017
    101.Zhang J, Li X, Huang R, Feng WL, Kong YN, Xu F6, Zhao L, Song QK2, Li J, Zhang BN, Fan JH, Qiao YL, Xie XM, Zheng S, He JJ, Wang K. A nomogram to predict the probability of axillary lymph node metastasis in female patients with breast cancer in China: A nationwide, multicenter, 10-year epidemiological study. Oncotarget. 2016 Nov 12. doi: 10.18632/oncotarget.13330. [Epub ahead of print]
    102.Zhang W, Zhang ZZ, Tang LY, Lin Y, Su FX, Xie XM, Su XF, Ren ZF. Genetic variants in EBV reactivation-related genes and the risk and survival of breast cancer. Tumour Biol. 2016 Jun;37(6):8337-47. doi: 10.1007/s13277-015-4562-0.
    103.Zhang BL, Sivasubramaniam PG, Zhang Q, Wang J, Zhang B, Gao JD, Tang ZH, Chen GJ, Xie XM, Wang Z, Yang HJ, He JJ, Li H, Li JY, Fan JH, Wang X, Qiao YL. Trends in Radical Surgical Treatment Methods for Breast Malignancies in China: A Multicenter 10-Year Retrospective Study. Oncologist. 2015 Sep;20(9):1036-43.
    104.Zhang B, Song Q, Zhang B, Tang Z, Xie X, Yang H, He J, Li H, Li J, Li J, Fan J, Huang R, Zhang H, Qiao Y. A 10-year (1999 ~ 2008) retrospective multi-center study of breast cancer surgical management in various geographic areas of China. Oncologist. 2015 Sep;20(9):1044-50. doi: 10.1634/theoncologist.2014-0290. 
    105.Tang H, Liu Q, Liu X, Ye F, Xie X, Xie X, Wu M. Plasma miR-185 as a predictive biomarker for prognosis of malignant glioma.J Cancer Res Ther. 2015 Jul-Sep;11(3):630-4. 
    106.Wang Z, Wang N, Liu P, Peng F, Tang H, Chen Q, Xu R, Dai Y, Lin Y, Xie X, Peng C, Situ H.Caveolin-1, a stress-related oncotarget, in drug resistance. Oncotarget. 2015 Sep 27. [Epub ahead of print.
    107.Sivasubramaniam PG, Zhang BL, Zhang Q, Smith JS, Zhang B, Tang ZH, Chen GJ, Xie XM, Xu XZ, Yang HJ, He JJ, Li H, Li JY, Fan JH, Qiao YL. Breast Cancer Disparities: A Multicenter Comparison of Tumor Diagnosis, Characteristics, and Surgical Treatment in China and the U.S. Oncologist. Oncologist. 2015 Sep;20(9):1044-50.
    108.Wang N, Wang Z, Wang Y, Xie X, Shen J, Peng C, You J, Peng F, Tang H, Guan X, Chen J . Dietary compound isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast .cancer stem cells through WIF1 demethylation. Oncotarget. 2015 Apr 30;6(12):9854-76.
    109.Zhang Y, Chen Y, Chen D, Jiang Y, Huang W, Ouyang H, Xing W, Zeng M, Xie X, Zeng W.Impact of preoperative anemia on relapse and survival in breast cancer patients.BMC Cancer. 2014 Nov 18;14:844. doi: 10.1186/1471-2407-14-844.
    110.Song QK, Li J, Huang R, Fan JH, Zheng RS, Zhang BN, Zhang B, Tang ZH, Xie XM, Yang HJ, He JJ, Li H, Li JY, Qiao YL, Chen WQ. Age of diagnosis of breast cancer in china: almost 10 years earlier than in the United States and the European union. Asian Pac J Cancer Prev. 2014;15(22):10021-5.
    111.Zhou C, He Jj, Li J, Fan Jh, Zhang B, Yang Hj, Xie Xm, Tang Zh, Li H, Li Jy, Wang Sl, Qiao Yl, Huang R, Zhang P. A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer. PLoS One. 2014 Jul 18;9(7):e100159. doi: 10.1371/journal.pone.0100159. eCollection 2014.
    112.Xie Z, Wang X, Lin H, Wei W, Liu P, Xiao X, Xie X, Guan X, Yang M, Tang J. Breast-conserving therapy: a viable option for young women with early breast cancer--evidence from a prospective study. Ann Surg Oncol. 2014 Jul;21(7):2188-96. doi: 10.1245/s10434-014-3620-y. Epub 2014 Mar 6.
    113.Li J, Huang Y, Zhang BN, Fan JH, Huang R, Zhang P, Wang SL, Zheng S, Zhang B, Yang HJ, Xie XM, Tang ZH, Li H, He JJ, Hsieh E, Qiao YL, Li JY. Body mass index and breast cancer defined by biological receptor status in pre-menopausal and post-menopausal women: a multicenter study in China. PLoS One. 2014 Jan 29;9(1):e87224. 
    114.Lee H, Li JY, Fan JH, Li J, Huang R, Zhang BN, Zhang B, Yang HJ, Xie XM, Tang ZH, Li H, He JJ, Wang Q, Huang Y, Qiao YL, Pang Y. Risk factors for breast cancer among Chinese women: a 10-year nationwide multicenter cross-sectional study. J Epidemiol. 2014;24(1):67-76. Epub 2013 Nov 23.
    115.Song Q, Huang R, Li J, Fan J, Zheng S, Zhang B, Yang H, Tang Z, He J, Xie X, Li H, Li J, Qiao Y. The Diverse Distribution of Risk Factors between Breast Cancer Subtypes of ER, PR and HER2: A 10-Year Retrospective Multi-Center Study in China. PLoS One. 2013 Aug 20;8(8):e72175. doi: 10.1371/journal.pone.0072175.
    116.Li L, Luo J, Wang B, Wang D, Xie X, Yuan L, Guo J, Xi S, Gao J, Lin X, Kong Y, Xu X, Tang H, Xie X, Liu M.Microrna-124 targets flotillin-1 to regulate proliferation and migration in breast cancer. Mol Cancer. 2013 Dec 13;12:163. doi: 10.1186/1476-4598-12-163.
    117.Song Q, Huang R, Li J, Fan J, Zheng S, Zhang B, Yang H, Tang Z, He J, Xie X, Li H, Li J, Qiao Y.The diverse distribution of risk factors between breast cancer subtypes of ER, PR and HER2: a 10-year retrospective multi-center study in China. PLoS One. 2013 Aug 20;8(8):e72175. doi: 10.1371/journal.pone.007217
    118.Wang SL, Li YX, Zhang BN, Li J, Fan JH, He JJ, Song QK, Zhang P, Zheng S, Zhang B, Yang HJ, Xie XM, Tang ZH, Li H, Li JY, Qiao YL. Epidemiologic study of radiotherapy use in China in patients with breast cancer between 1999 and 2008. Clin Breast Cancer. 2013 Feb;13(1):47-52. doi: 10.1016/j.clbc.2012.09.012. Epub 2012 Oct 25.
    119.Wang SL, Li YX, Zhang BN, Li J, Fan JH, Pang Y, Zhang P, Zheng S, Zhang B, Yang HJ, Xie XM, Tang ZH, Li H, Li JY, He JJ, Qiao YL. Epidemiologic study of compliance to postmastectomy radiation therapy guidelines in breast cancer patients in China between 1999 and 2008. Pract Radiat Oncol. 2013 Jul-Sep;3(3):209-15. 
    120.Zhang B, Song Q, Zhang B, Tang Z, Xie X, Yang H, He J, Li H, Li J, Li J, Fan J, Huang R, Zhang H, Qiao Y A 10-year (1999 ~ 2008) retrospective multi-center study of breast cancer surgical management in various geographic areas of China.Breast. 2013 Oct;22(5):676-81. doi: 10.1016/j.breast.2013.01.004.
    121.Cen YL, Qi ML, Li HG, Su Y, Chen LJ, Lin Y, Chen WQ, Xie XM, Tang LY, Ren ZF. Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen/progesterone receptor status. Mol Carcinog. Mol Carcinog. 2013 Nov;52 Suppl 1:E52-9. doi: 10.1002/mc.21979. 
    122.Zhang BN, Zhang B, Tang ZH, Xie XM, Yang HJ, He JJ, Li H, Li JY, Li J, Fan JH, Huang R, Song QK, Zhang HM, Qiao YL.10-year changes and development of surgical treatment for breast cancer in China. Zhonghua Zhong Liu Za Zhi. 2012 Aug;34(8):582-7. doi: 10.3760/cma.j.issn.0253-3766.2012.08.005. Chinese.
    123.Ge QD, Lv N, Kong YN, Xie XH, He N, Xie XM, Wei WD. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases. Asian Pac J Cancer Prev. 2012;13(10):5081-6.
    124.Su Y, Tang LY, Chen LJ, He JR, Su FX, Lin Y, Chen WQ, Xie XM, Ren ZF.Joint effects of febrile acute infection and an interferon-γ polymorphism on breast cancer risk. PLoS One. 2012;7(5):e37275. doi: 10.1371/journal.pone.0037275. Epub 2012 May 18.
    125.Ge QD, Lv N, Cao Y, Wang X, Tang J, Xie ZM, Xiao XS, Liu P, Xie XM, Wei WD. A case report of primary small cell carcinoma of the breast and review of the literature. Chin J Cancer. 2012 Jul;31(7):354-8. doi: 10.5732/cjc.012.10012. Review.
    126.Ma X, Beeghly-Fadiel A, Lu W, Shi J, Xiang YB, Cai Q, Shen H, Shen CY, Ren Z, Matsuo K, Khoo US, Iwasaki M, Long J, Zhang B, Ji BT, Zheng Y, Wang W, Hu Z, Liu Y, Wu PE, Shieh YL, Wang S, Xie X, Ito H, Kasuga Y, Chan KY, Iwata H, Tsugane S, Gao YT, Shu XO, Moses HL, Zheng W. Pathway Analyses Identify TGFBR2 as Potential Breast Cancer Susceptibility Gene: Results from a Consortium Study among Asians. Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1176-84. doi: 10.1158/1055-9965.EPI-12-0118. (IF:4.123)
    127.Wang Q, Li J, Zheng S, Li JY, Pang Y, Huang R, Zhang BN, Zhang B, Yang HJ, Xie X, Tang ZH, Li H, He JJ, Fan JH, Qiao YL. Breast cancer stage at diagnosis and area-based socioeconomic status: a multicenter 10-year retrospective clinical epidemiological study in China. BMC Cancer. 2012 Mar 29;12:122. (IF:3.153)
    128.Long J, Cai Q, Sung H, Shi J, Zhang B, Choi JY, Wen W, Delahanty RJ, Lu W, Gao YT, Shen H, Park SK, Chen K, Shen CY, Ren Z, Haiman CA, Matsuo K, Kim MK, Khoo US, Iwasaki M, Zheng Y, Xiang YB, Gu K, Rothman N, Wang W, Hu Z, Liu Y, Yoo KY, Noh DY, Han BG, Lee MH, Zheng H, Zhang L, Wu PE, Shieh YL, Chan SY, Wang S, Xie X, Kim SW, Henderson BE, Le Marchand L, Ito H, Kasuga Y, Ahn SH, Kang HS, Chan KY, Iwata H, Tsugane S, Li C, Shu XO, Kang DH, Zheng W. Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer. PLoS Genet. 2012 Feb;8(2):e1002532. Epub 2012 Feb 23. (IF :9.543 )
    129.Shao YZ, Liu LZ, Bie MJ, Li CC, Wu YP, Xie X, Li L. Characterizing the clustered microcalcifications on mammograms to predict the pathological classification and grading: a mathematical modeling approach. J Digit Imaging. 2011 Oct;24(5):764-71. (IF:1.413 )
    130.Lv N, Xie X, Ge Q, Lin S, Wang X, Kong Y, Shi H, Xie X, Wei W. Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations. Diagn Pathol. 2011 Dec 2;6(1):118. (IF: 1.388)
    131.Liu Y, Lang F, Xie X, Prabhu S, Xu J, Sampath D, Aldape K, Fuller G, Puduvalli VK. Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts. Cell Death Dis. 2011 Feb 24;2:e121.(IF:5.333)
    132.Li J, Zhang BN, Fan JH, Pang Y, Zhang P, Wang SL, Zheng S, Zhang B, Yang HJ, Xie X, Tang ZH, Li H, Li JY, He JJ, Qiao YL. A Nation-Wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in china. BMC Cancer. 2011 Aug 22;11:364. (IF:3.153)
    133.Xie ZM, Li LS, Laquet C, Penault-Llorca F, Uhrhammer N, Xie X, Bignon YJ. Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer. Cancer. 2011; 117 (14): 3112-17.(IF: 5.131)
    134.Xiao X, Shi D, Liu L, Wang J, Xie X, Kang T, Deng W. Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of P300 signaling. PLoS One. 2011;6(8):e22934. Epub 2011 Aug 8. (IF: 4.411)
    135.Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC. BikDD Eliminates Breast Cancer Initiating Cells and Synergizes with Lapatinib for Breast Cancer Treatment. Cancer Cell. 2011 Sep 13;20(3):341-56.( IF: 26.925)
    136.Cai Q, Long J, Lu W, Qu S, Wen W, Kang D, Lee JY, Chen K, Shen H, Shen CY, Sung H, Matsuo K, Haiman CA, Khoo US, Ren Z, Iwasaki M, Gu K, Xiang YB, Choi JY, Park SK, Zhang L, Hu Z, Wu PE, Noh DY, Tajima K, Henderson BE, Chan KY, Su F, Kasuga Y, Wang W, Cheng JR, Yoo KY, Lee JY, Zheng H, Liu Y, Shieh YL, Kim SW, Lee JW, Iwata H, Le Marchand L, Chan SY, Xie X, Tsugane S, Lee MH, Wang S, Li G, Levy S, Huang B, Shi J, Delahanty R, Zheng Y, Li C, Gao YT, Shu XO, Zheng W.Genome-wideassociation study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium. Hum Mol Genet. 2011 Dec 15;20(24):4991-9. (IF : 8.058)
    137.Ding Q, Chang CJ, Xie X, Xia W, Yang JY, Wang SC, Wang Y, Xia J, Chen L, Cai C, Li H, Yen CJ, Kuo HP, Lee DF, Lang J, Huo L, Cheng X, Chen YJ, Li CW, Jeng LB, Hsu JL, Li LY, Tan A, Curley SA, Ellis LM, Dubois RN, Hung M.APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest. 2011 Nov 1;121(11):4526-36. (IF : 14.152)
    138.Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN, Hung MC. EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β Catenin Signaling. Cancer Cell. 2011;19:86-100 ( IF: 26.925)
    139.Song H, Li CW, Labaff AM, Lim SO, Li LY, Kan SF, Chen Y, Zhang K, Lang J, Xie X, Wang Y, Huo LF, Hsu SC, Chen X, Zhao Y, Hung  MC. Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors. Biochem Biophys Res Commun. 2011 Jan 7;404(1):68-73. (IF:2.595)
    140.Tang J, X Xie, X Wang,  Z Xie, J He, Y Wu, W Fan, J Fu and M Yang. Radiocolloid in combination with methylene dye localization, rather than wire localization, is a preferred procedure for excisional biopsy of nonpalpable breast lesions. Ann Surg Oncol. 2011 Jan;18(1):109-13. (IF :4.182)
    141.Kuo HP, Lee DF, Chen CT, Liu M, Chou CK, Lee HJ, Du Y, Xie X, Wei Y, Xia W, Weihua Z, Yang JY, Yen CJ, Huang TH, Tan M, Xing G, Zhao Y, Lin CH, Tsai SF, Fidler IJ, Hung MC. ARD1 Stabilization of TSC2 Suppresses Tumorigenesis Through the mTOR Signaling Pathway. Science Signaling. 2010 Feb 9;3(108). ( IF: 6.354)
    142.Sher YP, T-F Tzeng, S-F Kan, J Hsu, X Xie, Z Han, W-C Lin, L-Y Li, and M-C Hung. Cancer Targeted Gene Therapy of BikDD Inhibits Orthotopic Lung Cancer Growth and Improves Long-Term Survival. Oncogene. 2009;28(37):3286-95. (IF :7.216).
    143.Yang, J-Y., Zong, C.S., Xia, W., Yamaguchi, H., Ding, Q., Xie, X., Lang, J-Y., Lai, C-C., Chang, C-J., Huang, W-C., Huang, H., Kuo, H-P., Lee, D-F., Li, L-Y., Lien H-C., Cheng, X, Chang, K-J., Hsiao, C-D., Tsai, F-J., Tsai, C-H., Sahin, AA., Hortobagyi, GN., Yu, D., Muller, WJ., Mills, GB., and Hung, M-C. Erk promotes tumorigenesis by inhibiting Foxo3a via MDM2-mediated degradation. Nature Cell Biology. 2008; 10(2):138-48.. (IF:19.47).
    144.Ding, Q., He, X., Xia, W., Hsu, J-M., Chen, C-T., Li, L-Y., Lee, D-F., Yang, J-Y., Xie, X., Liu, J-C., and Hung, M-C. Mcl-1 inversely correlates with GSK-3β activity and associates with poor prognosis in human breast cancer. Cancer Research, 2007;67(10):4564-71. (IF:8.234). 
    145.Seethammagari, M. R., Xie, X., Greenberg, N. M., and Spencer, D. M. (2006). EZC-prostate models offer high sensitivity and specificity for noninvasive imaging of prostate cancer progression and androgen receptor action. Cancer Res 2006;66, 6199-6209. (IF: 8.234). 
    146.Ou-Yang, F., Lan, K. L., Chen, C. T., Liu, J. C., Weng, C. L., Chou, C. K., Xie, X., Hung, J. Y., Wei, Y., Hortobagyi, G. N., Hung, M-C. Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells. Cancer Res 2006; 66, 378-384. (IF:8.234).
    147.Day, C. P., Rau, K. M., Qiu, L., Liu, C. W., Kuo, H. P., Xie, X., Lopez-Berestein, G., Hortobagyi, G. N., and Hung, M. C.. Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Ther 2006;13, 706-719. (IF: 3.744).
    148.Tuttle, D. L, CR Coberley, X Xie, ZC Kou, JW Sleasman, and MM Goodenow. Effects of human immunodeficiency virus type 1 infection on CCR5 and CXCR4 coreceptor expression on CD4 T lymphocyte subsets in infants and adolescents. AIDS Res Hum Retroviruses. 2004. 20(3): 305-13. (IF : 2.139).
    149.Zhao T, XM Rao, X Xie, L Li, T Thompson, KM McMasters, and HS Zhou. Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo. Cancer Res 2003;63(12):3073-8. (IF:8.234).
    150.M Drozdzik, C Qian, X Xie, JJ Lasarte, J Prieto. Gene therapy of hepatoma model by combination of adenovirus expressing the HSV thymidine kinase and interleukin-12. J Hepatology. 2000; 32(2): 379-86. (IF:9.334)
    151.Mazzolini G, C Qian, I Narvaiza, M Barajas, F Borras-Cuesta X Xie, M Duarte, I Melero and J Prieto. Adenoviral gene transfer of Interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effect level. Human Gene Therapy 2000; 11:113-25. (IF: 4.829).
    152.Lasarte JJ, FJ Corrales, N Casares, A Lopez-Diaz de Cerio, C Qian, X Xie, F Borras-Cuesta, and J Prieto. Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministrered antigen: the role of nitric oxide. J Immunology, 1999; 162:5270-5277. (IF:5.745)
    153.Mazzolini G, C Qian, X Xie, Y Sun, JJ Lasarte M, Drozdzik, J Prieto. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Therapy, 1999; 6(6): 514-22. . (IF: 3.744)
    154.Lau J Y-N, X Xie, MMC Lai, and PC Wu. Apoptosis and viral hepatitis. Seminar in Liver Disease 1998; 18(2):169-176.(IF : 7.053)

    (中文論文25篇):
    155.黃曉嘉,唐海林,謝小明.程序性死亡配體1 在三陰性乳腺癌中的研究進展. 中華乳腺病雜志(電子版) 2017;11(4):234-237
    156.謝新華,韋尉東,孔亞楠,郭姣麗,呂寧,唐軍,肖祥勝,謝小明*。藥物代謝酶CYP2D6在他
    莫西芬個體化治療中的研究進展。中華乳腺病雜志。 2011;5(5):49-55
    157.尹軍,唐軍,王曦,謝澤明,連臻強,謝小明,楊名添。乳暈下注射示蹤劑行前哨淋巴結活檢的可行性。 中華乳腺病雜志,2008,2(5):514-519。
    158.夏良平,周菲菲,楊名添,謝小明.乳腺癌中基因標簽研究的共性問題.國際腫瘤學雜志, 2009.36(4)。
    159.韋尉東 謝小明. 后曲妥珠單抗時代的乳腺癌靶向治療.廣東醫學。2010;31(2). 133-136。
    160.呂寧,孔亞楠,謝小明,韋尉東。乳腺癌抗-EGFR 治療的機制和臨床進展。廣東醫學。2010;31(21)2874-2876。
    161.肖祥勝 李峻 王曦 韋尉東 唐軍 劉鵬 謝小明。青年乳腺癌209例生存分析。中國醫師進修雜志。 2010.
    162.謝小明, 蘇先獅, 張錚. 逆轉錄-套式-聚合酶鏈反應檢測HCV RNA正鏈和負鏈及與肝細胞癌的關系. 中華傳染病雜志. 1996; 14(4): 211-213
    163.蔡太生,謝小明,王麗. 慢性乙肝病人的心理健康狀況及相關因素的調查分析. 中國臨床心理學雜志. 1996; 4(2): 111-113
    164.謝小明,蘇先獅, 張錚. 丙型肝炎病毒與肝細胞癌關系的分子生物學研究進展. 國外醫學:生理病理科學與臨床分冊. 1995; 15(2): 106-108
    165.謝小明, 蘇先獅, 張錚, 鄭宣鶴, 楊旭, 曾曉波, 陳一德, 李良友, 劉國清, 皮執民, 黃江生.肝癌患者丙型肝炎病毒感染的研究. 中國現代醫學雜志. 1994; 4(1): 27-28
    166.謝小明, 蘇先獅,張錚, 鄭宣鶴, 陳一德. 聚合酶鏈反應研究丙型肝炎病毒與肝癌的關系. 中華傳染病雜志.1994; 12(3): 169-170
    167.謝小明, 蘇先獅, 陳一德, 李良友, 鄭宣鶴, 曾滑, 吳衛民, 劉遠芳. 肝癌患者血清乙型肝炎病毒標志物和抗丙型肝炎病毒抗體的檢測及其相互關系. 醫學臨床研究. 1994; 11(2): 64-66
    168.鄭煜煌, 金一平, 謝小明, 張雪梅, 蔣芳清, 王計全 , 易長庚. 甲型肝炎患者外周血T淋巴細胞集落和T淋巴細胞亞群的觀察. 中華傳染病雜志. 1994; 12(1): 49-50
    169.謝小明. 無癥狀供血者和慢性丙型肝炎患者血清HCV RNA的定量研究. 國際流行病學傳染病學雜志. 1993; 20(5): 228-228
    170.謝小明, 鄭煜煌, 劉遠芳, 金一平, 劉雪梅, 蔣芳清, 王計壘, 易長庚. 甲型肝炎患者外周血T淋巴細胞亞群的觀察. 醫學臨床研究. 1993; 10(5): 260-261
    171.謝小明, 蘇先獅, 張錚, 陳一德, 李良友, 鄭宣鶴, 劉國清, 皮執民, 周健平, 齊海智. 乙型、丙型和丁型肝炎病毒與肝細胞癌島關系. 中西醫結合肝病雜志. 1993;3 (2): 6-7
    172.蘇先獅, 謝小明, 陳一德, 楊觀生. 湖南供血員和肝病患者1272例血清抗HCV檢測及甲乙丙丁各型肝炎混合感染的研究. 臨床肝膽病雜志. 1993; 9(1): 10-11
    173.蘇先獅, 鄭宣鶴, 錢煥英, 王谷豐, 鄧純, 劉麗霞, 彭蘭莎, 謝小明. 肝臟刺激生長素(HSS)治療病毒性肝炎300例的臨床研究. 臨床肝膽病雜志. 1992; 8(3): 126-127
    174.鄭煜煌, 謝小明. 甲型肝炎患者外周血T淋巴細胞集落的觀察. 廣西醫學, 1992; 6(6): 4-5
    175.鄭宣鶴, 龔國忠, 何艷, 黃道芩, 謝小明.急性肝炎重型并發急性容血性貧血和類白血病反因二例. 中華傳染病雜志. 1991; 9(1): 32-33
    176.鄭煜煌, 謝小明, 張永紅, 何艷. 病毒性肝炎患者中肥達反應的動態觀察. 醫學臨床研究. 1990; 7(3): 167-169

    主編專著
    1.謝小明等。乳腺癌個體化治療(第十八章)《腫瘤個體化醫學原則》,人民衛生出版社。 2013.p 227-241
    2.謝小明等。乳腺疾病相關的分子生物學(第三章第四節)《現代乳腺外科》, 人民衛生出版社2014.p92-103.
    3.謝小明等。乳腺癌的危險因素(第14章)《乳腺疾病學》, 人民衛生出版社2017.p155-164.
    4.Mien-Chie Hung, JL Hsu, CH Chao, Xiaoming Xie. Advances in Liposome-Based Targeted Gene Therapy of 《Cancer Recent Advances in Cancer Research and Therapy》,Elsevier,18 May 2012
    5.Wang Z, Wang N, Liu P, Xie X. AMPK and Cancer. EXS. 2016;107:203-226.

    部分國際會議(*為第一作者或通信作者文摘):
    *1. The 8th International Conference on Viral Hepatitis. Xie X, X  Su, et al. A comparative study of on the relationship of HBV, HCV and HDV with hepatocellular carcinoma. Beijing, China. 1993北京
    *2. The annual meeting of the Association for the Study of Liver Diseases. Xie, et al. In vivo gene transfer to hepatocullular carcinoma in experimental animal models by adenoviral vector. London, 1996. 倫敦
    *3. The 2rd annual meeting of the Europe Society of Gene Therapy. X Xie, M Idoato and J Prieto. In vivo gene transfer to hepatocullular carcinoma by adenoviral vector. London, 1998. 西班牙
    *4. The 48th annual meeting of the American Association for the Study of Liver Diseases. Xie X, CE Forsmark and JYN Lau. Feasibility of adenoviral-mediated gene delivery through EGFP: the effect of bile and pancreatic juice. Chicago, USA, 1997. 芝加哥
    *5. The 6th Conference on retroviruses and Opportunistic Infections. Xie X, D Turtle, J.W. Sleasman and M.M. Goodenow . CD4 T lymphocytes that coexpress CD45RO and CD45RA are the primary target cells for infection by HIV-1. Chicago, USA, 1999. 芝加哥
    *6. The 3rd annual meeting of the American Society of Gene Therapy, Xie X, Spencer D. Robust prostate cell-specific expression based on human kallikrein 2(hK2) has been developed for targeted gene therapy. Denver, USA, 2000. 丹佛
    *7. The 4th annual meeting of the American Society of Gene Therapy, Xie X, Spencer D. Adenovirus-mediated tissue-targeted expression of a caspase 9-based artificial death switch for the treatment of prostate cancer. Seattle, USA, 2001. 西雅圖
    *8. The 5th annual meeting of the American Society of Gene Therapy, Xie X, Spencer D. Novel gene therapy for prostate cancer: in vivo-targeted expression of the E.Coli purine nucleoside phsophorylase gene by adenoviral delivery. Boston, USA, 2002. 波士頓
    *9. The 6th annual meeting of the American Society of Gene Therapy, Xie X, Spencer D. Novel prostate model. Washington DC, USA, 2003. 華盛頓
    *10. The 8th annual meeting of the American Society of Gene Therapy, Xie X, et al. Targeted prostate cancer gene therapy (oral presentation). St. Louis, USA, 2005圣路易斯
    *11. The 10th annual meeting of the American Society of Gene Therapy, Xie X, et al. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models (oral presentation). Seattle, USA, 2007. 西雅圖
    *12. IMPcCT (Innovative Minds in Prostate Cancer Today), Department of Defense. Xie X, et al. Targeted expression of BikDD cures AIPC and ADPC in noninvasive imaging models. Atlanta, USA, 2007.
    13. The 5th Chinese Conference on Cancer and International Gene Therapy. Shijianzhuan, Hebei,China, 2008.
    *14. The 15th World Congress on Breast Diseases and 3rd Shanghai Breast Cancer Symposium. Shanghai, China, Oct. 2008. 上海
    15. The San Antonio Breast Cancer Symposium at An Antonio, USA. Dec 10-15. 2008. 圣奧東尼奧
    *16.  The 5th Conference on Cancer Translational Research. Xie et al.  “VISA” nanopaticles to breast cancer.  Feb. 19-21. 2009. Macau. 
    17. The St Gallen Oncology Conference in Switzerland.  March 11-15, 2009. 瑞士
    18. The 45th Annual Meeting of the American Society of Clinical Oncology. Orlando, USA. May 28-June 3.  2009. 奧爾蘭多
    *19. the 14th Annual Scientific Symposium of Hong Kong Cancer Institute-Breast Cancer Symposium. Xie X, et al.“VISA” nanopaticles targeting to breast cancer. Nov. 11-14. Hong Kong. 香港
    *20. The San Antonio Breast Cancer Symposium at San Antonio. Xiaoming Xie,  et al. “VISA” nanopaticles to breast cancer. USA. Dec 9-14. 2009. 圣奧東尼奧
    *21. The 46th Annual Meeting of the American Society of Clinical Oncology. “VISA” nanopaticles to breast cancer  in animal models. Chicago, USA. June 3-June 8. 2010. 芝加哥
    *22. The San Antonio Breast Cancer Symposium at San Antonio. Xiaoming Xie,  et al. “VISA” nanopaticles targeting to breast cancer in vitro and in animal models. USA. Dec 8-12. 2010. 圣奧東尼奧
    *23. The 47th Annual Meeting of the American Society of Clinical Oncology. “VISA” nanopaticles to breast cancer in animal models. Chicago, USA. June 3-June 8. 2011. 芝加哥
    *24. The 16th Annual Scientific Symposium of Hong Kong Cancer Institute-Breast Cancer Symposium. Xie X, et al.“VISA-miRNAs” nanopaticles target to breast cancer. Nov. 4-6. Hong Kong. 香港
    *25. The San Antonio Breast Cancer Symposium at San Antonio. Xiaoming Xie,  et al.. USA. Dec 6-10. 2011. 圣奧東尼奧
    *26. The 48th Annual Meeting of the American Society of Clinical Oncology. “VISA” nanopaticles to breast cancer in animal models. Chicago, USA. June 1-5. 2012. 芝加哥
    *27. The 2nd  International Conference on Cell Science and Stem Research. “VISA-BikDD” and “VISA-miRNA” nanoparticles targeting to breast cancer and breast cancer stem cells. Invited Speaker. San Antonio. OMICS Group Conference. USA. Nov. 14-15, 2012. 圣奧東尼奧
    *28. The San Antonio Breast Cancer Symposium at San Antonio. VISA-miRNA and VISA-BikDD nanopaticles targeting to breast cancer.. USA. Dec 4-8. 2012. 圣奧東尼奧
    *29. China Cancer Conference. VISA- nanopaticles targeting to breast cancer stem cells. Beijing, Nov. 17-18. 2013. China
    30. The 49th Annual Meeting of the American Society of Clinical Oncology. Chicago, USA. June , 2013. 芝加哥
    *31. The San Antonio Breast Cancer Symposium at San Antonio. VISA nanopaticles targeting to breast cancer.. USA. Dec 8-12. 2013. 圣奧東尼奧
    32. The 50th Annual Meeting of the American Society of Clinical Oncology. Chicago, USA. June , 2014. 芝加哥
    *33. The San Antonio Breast Cancer Symposium at San Antonio. VISA nanopaticles to breast cancer.. USA. Dec 8-12. 2014. 圣奧東尼奧
    *34. The 51th Annual Meeting of the American Society of Clinical Oncology. Chicago, USA. June , 2015. 芝加哥
    *35. The San Antonio Breast Cancer Symposium at San Antonio... USA. Dec 6-10. 2015. 圣奧東尼奧
    *36. The 52th Annual Meeting of the American Society of Clinical Oncology. Chicago, USA. June , 2016. 芝加哥

    新聞與報道:
    1.納米顆粒介導的VISA系統靶向治療胰腺癌的主要研究成果,已發表2007年7月份的Cancer Cell 
    (IF:24.962)上。美國約翰霍普金斯大學醫學院的胰腺癌專家Scott E. Ken教授,在 Science News 上評論:“這種治胰腺癌的方法是獨一無二的,對胰腺癌既有非常強的療效又非常特異”。美國ABC電視臺認為“是胰腺癌治療的一個重大突破”。來自美國、中國、俄國、德國、法國、西班牙、葡萄牙、意大利、荷蘭、希臘、阿拉伯、韓國本等世界各的科學雜志和新聞媒體對該成就紛紛進行了200多次報道,并給予了高度的價。
    2.中國醫學論壇。2010.1
    3.廣東醫師協會。 2010.9
    4.南方都市報。2008.10
    5.羊城晚報。 2012.3
    6.鳳凰網;番禺日報。廣州首屆公益創投項目“醫路同行——關愛腫瘤病人”2014.
    7.中央人民廣播電臺,2014
    8.廣州日報,吃火腿香腸會致癌? 不是天天吃大量吃就沒事。2015
    9.新快報。夜班工作會增加患乳腺癌風險?是真的。2015.
    10.醫師報。積極應對乳腺癌的復雜性與異質性
    11.科技日報;健康報健康資訊;中國健康網。溫州網 .執 著 的 追 求--記中山大學腫瘤防治中心乳腺科主任謝小明教授. 2016.2
    12.羊城晚報。得了乳腺癌,還能圓當媽媽的夢嗎?2017.
    13.南方健客網。粉紅健康用愛呵護。2017

    部分獲獎:
    1.the 14th Hong kong Breast Cancer Conference 最佳獎, 2011, 香港.
    2.AstraZeneca Award ($50,000). USA. 2005. 美國.
    3.First prize, the 10th Annual Oncology Research Seminar. USA. 2001. 美國.
    4.Travel Grant, the 6th Conference on retroviruses and Opportunistic Infections, USA. 1999. 美國.
    5.The best oral presentation award. Terapia genica del hepatocarcinoma mediate la transferencia del gen  la interlukina 12 y timidin kinasa mediada por adenovirus.Madrid, Spain. 1998. 西班牙.
    6.Dr. Sir Q.W. Lee fellowship. USA. 1997. 美國.
    7.Dr. Li Zhengbie’s Fellowship. China. 1994. 長沙.
    8.Challenge Cup of China’s invention. China.1993. 挑戰杯獎,上海.
    9.<<湘楚青年科技名人錄>> (1993年).
    10.<<當代發明家成果辭典>> (1994年).
    11.<<當代科學家與發明家大詞典>> (1994年).
    12.<<國際名人詞典>> (第23版). 英國國際人物中心轉記編輯出版,1994年. <<DICTIONARY OF INTERNATIONAL BIOGRAPHY>> (Twenty-third Edition). 
    13.Who's Who in the World? 2016 (33rd Edition).
    14.2018 Albert Nelson Marquis Lifetime Achievement Award.

    學會會員和社會兼職: 
    1.美國科學促進會(AAAS)(1998年)
    2.美國基因治療協會(ASGT)會員 (1999年)
    3.美國 Sigma Xi 科學研究會會員(2000年)
    4.美國癌癥研究協會會員(AACR),(2004年)
    5.美國臨床癌癥研究協會會員(ASCO)(2008年)
    6.《Global Journal of Epidemiology and Public Health》共同主編
    7.《Journal of Tumor》, Hong Kong. Associated editor,
    8.美國《Journal of Cancer》編委
    9.《Chinese Journal of Cancer》責任編委
    10.《中華乳腺病雜志》編委
    11.《腫瘤學雜志》編委
    12.中華醫學會腫瘤分會乳腺癌專業委員會委員
    13.中華醫學會整形外科學分會腫瘤整形外科學委員
    14.國家自然科學基金委評審一審專家
    15.國家自然科學基金委評審二審專家
    16.國家博士后基金評審專家
    17.中國研究型醫院學會乳腺專業委員會常委
    18.中國抗癌協會腫瘤代謝委員會委員
    19.中國健康促進會乳腺癌防治專家
    20.衛生部醫療服務標準專業委員會專家
    21.教育部學位評審專家
    22.廣東省抗癌協會乳腺癌專業委員會常委
    23.廣東省醫學會乳腺病分會常委
    24.廣東省醫師協會乳腺??漆t師工作委員會常委
    25.廣東省保健協會首席專家
    26.廣東省胸部腫瘤防治研究會乳腺癌專業委員會副主委
    27.廣東省自然科學基金委評審專家
    28.廣東省醫學鑒定專家
    29.廣東省和諧醫療糾紛協調專家
    30.廣州市醫療事故技術鑒定專家
    31.嶺南名醫
    32.羊城好醫生


    更新日期:2019年5月24日
訪客通道
員工通道
關注腫瘤醫院
留言建議 ×
沙巴体育下载